Oct 18 (Reuters) - NuCana PLC NCNA.O:
NUCANA PRESENTS ENCOURAGING DATA ON NUC-7738 IN COMBINATION WITH PD-1 INHIBITORS USING PRIMARY PATIENT-DERIVED ORGANOIDS AND AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTES AT THE ESMO CONGRESS 2025
NUCANA PLC - REGULATORS APPROVE STUDY EXPANSION FOR 28 MORE PATIENTS
NUCANA PLC - DATA TO DATE FROM NUTIDE:701 SHOWS FAVORABLE SAFETY AND TUMOR REDUCTION